- Be Bio has raised $92M in Series C financing to advance its clinical-stage B Cell Medicines (BCM) platform.
- The funding will support clinical proof-of-concept for BE-101 in hemophilia B and BE-102 in hypophosphatasia.

Be Bio, has successfully closed a $92 million Series C financing round. The funding was backed by new investor Nextech, along with existing investors such as ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb, and Takeda Ventures. As part of the financing agreement, Melissa McCracken, Ph.D., a Partner at Nextech, will join Be Bio’s Board of Directors.
The funds raised will primarily be used to advance Be Bio’s two lead programs. The first, BE-101, is part of the ongoing BeCoMe-9 Phase 1/2 clinical trial for patients with hemophilia B. The second, BE-102, is set to enter clinical trials for the treatment of hypophosphatasia. Both programs are based on Be Bio’s BCM product platform, which aims to create durable, titratable, and redosable therapeutics without the need for preconditioning, providing sustained and constant levels of therapeutic proteins.
Joanne Smith-Farrell, Ph.D., CEO of Be Bio, expressed confidence in the company’s future: “With this funding in hand, we are well-equipped to advance our two lead programs and solidify our position as a multi-program, clinical-stage company. We are on track to demonstrate clinical proof-of-concept for BE-101 in Hemophilia B this year.”
Be Bio is poised to demonstrate the potential of BCMs as a new standard of care in enzyme replacement therapies, particularly for patients with rare diseases. Dr. Smith-Farrell further emphasized, “BE-102 is poised to enter the clinic next year, potentially demonstrating BCMs’ potential to become a new gold standard in enzyme replacement by providing hypophosphatasia patients with a transformative new option.”
Dr. McCracken, representing Nextech, added, “We are excited to partner with Be Bio at this pivotal stage. We believe BCMs, as a class, could revolutionize treatment paradigms across indications. We look forward to supporting their groundbreaking work and witnessing the transformative impact on patient care.”